Salmonella Typhi
PreclinicalBiologic
Salmonella Typhi is one of 9 biologic programs targeting Humans. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Humans
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Reboxetine
UUniversity of Zurich
Preclinical
Remitch
SShandong New Time Pharmaceutical Co., LTD
Preclinical
Salmonella Typhi
UUniversity of Oxford
Preclinical
Astaxanthin
SSheba Medical Center
Preclinical
Nalfurafine Hydrochloride
SShandong New Time Pharmaceutical Co., LTD
Preclinical
GLP-2
GGlostrup University Hospital, Copenhagen
Preclinical
Stool Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
PBR111
UUniversity of North Carolina, Chapel Hill
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Salmonella Typhi. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Oxford